Acción de los anti estrógenos y observaciones en el varón transexual (página 2)

34. Nayfield SG, Gorin MB.
Tamoxifen-associated eye disease. A review. J Clin Oncol 1996
Mar 14:3 1018-26

35. Nydick m, bustos j, dale j,
rawson r. Gynecomastia in adolescent boys. JAMA 196; 178:
449-54.

36. Oduwole OO, Makinen MJ, Isomaa
VV, Pulkka A, Jernvall P, Karttunen TJ, Vihko PT.
17Beta-hydroxysteroid dehydrogenase type 2: independent
prognostic significance and evidence of estrogen protection
in female patients with colon cancer. Steroid Biochem Mol
Biol 2003 Nov; 87(2-3): 133-140

37. Ortiz-Núñez DA,
Mengchún-López G, HernándezMarín
I, Mendoza R, Ayala-Ruiz AR. Ausenciade efecto
antiosteopénico de la terapia hormonal de reemplazo en
mujeres posmenopáusicas Ginecol Obstet Mex
2004;72:349-355

38. Osborne CK, Zhao HH, Fuqua
SAW. Selective estrogen receptor modulators: structure,
function, and clinical use. J Clin Oncol
2000;18:3172-86.

39. Pavone-Macaluso M, de Voogt
HJ, Viggiano G, Bertagna C, De Gery A, Hucher M, et
al.Comparison of diethystilbestrol, cyproterone acetate, and
medroxiprogesterone acetate in the treatement of advanced
prostate cáncer

40. Polin SA, Ascher SM. The
effect of tamoxifen on the genital tract. Cancer Imaging.
2008;8:135-45.

41. Riepe F, Baus I, Wiest S,
Krone N, Sippell W, Partsch C-J. Treatment of Pubertal
Gynecomastia with the Specific aromatase Inhibitor
Anastrozole. Horm Res 2004; 62: 113-8.

42. Riggs BL, Hartmann LC.
Selective estrogen-receptor modulators. Mechanisms of action
and application to clinical practice. N Engl J Med
2003;348:518-29

43. Robinson E, Kimmick GG, Muss
HB. Tamoxifen in postmenopausal women a safety perspective.
Drugs Aging 1996 May 8:5 329-37

44. Rodriguez RC, Esperon AA,
Ropero R, Rubio MC, Rodriguez R, Ortiz RM et al. Prevalence
of BRCA1 and BRCA2 mutations in breast cancer patients from
Cuba. Fam Cancer 2008;7: 275-279.

45. Santen RJ. Editorial: Long
term tamoxifen therapy: can an antagonist become an agonist?
J Clin Endocrinol Metab1996; 81: 2027-2029.

46. Tamimi R, Byrne C, Colditz G,
Hankinson S. Endogenous hormone levels, mammographic density,
and subsequent risk of breast cancer in postmenopausal women.
J Natl Cancer Inst 2007; 99:1178-87.

47. Vachon C, Kuni C, Anderson K,
Anderson E, Sellers T. Association of mammographically
defined percent breast density with epidemilogic risk factors
for breast cancer (United States). Cancer Causes and Control
2000; 11:653-662.

48. Wickerham L, Tan-Chiu E.
Quimioprevención del cáncer de mama: estado
actual e indicaciones futuras. Semen Oncol 2002;
1(1)35-41